Key Takeaways Labcorp Holdings, Inc. (LH) has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test helps through early detection of the amyloid plaques associated with the disease in appropriate patients. The latest test builds on and replaces a similar pTau-217/Beta Amyloid 42 Ratio test that Labcorp introduced in ...

Photo courtesy of Labcorp (PRNewsfoto/Labcorp) Photo courtesy of Labcorp (PRNewsfoto/Labcorp) Laboratory testing plays a critical role in healthcare, informing nearly 70% of clinical decisions and often serving as the first step in diagnosing and managing patient conditions. Yet research shows providers spend more than three hours a day on responsibilities including documentation and test ordering—time that could be spent with patients. According to a recent American Medical Association (AMA) survey, 57% of ...